LEXINGTON, Mass.--(BUSINESS WIRE)--KSQ Therapeutics, a clinical-stage biotechnology company developing therapies to treat cancer and autoimmune diseases using its proprietary, integrated discovery CRISPRomics platform, announced today that Ono Pharmaceutical Co., Ltd. ("ONO"), has acquired multiple research-stage DNA damage response (DDR) programs identified using KSQ's CRISPRomics platform technology. All the programs are novel and have the potential to become first-in-class therapies.

"This acquisition of multiple research-stage oncology programs by ONO is further validation of the power of our platform to identify novel oncology targets and develop potential first-in-class programs," said Qasim Rizvi, Chief Executive Officer of KSQ. "This is an important transaction for KSQ, enabling us to focus on our other programs. We look forward to watching ONO's progress as they advance these programs toward clinical studies."

"ONO appreciates the ability of KSQ's CRISPRomics platform technology to discover novel therapeutic targets with high selectivity for cancer cells," said Toichi Takino, Senior Executive Officer / Executive Director, Discovery & Research of ONO. "Through this acquisition agreement, we expect that the programs acquired from KSQ will lead to the creation of innovative medicines that will help treat cancer patients."

More on Boston Chron

• Entrinsik Board Announces New CEO
• Work & Mother Announces Collaboration with Jamestown to Provide State-of-the-Art Lactation Suites in Select Commercial Buildings
• Knobull Streamlines Presentation Techniques That Turns Stress Into Enjoyment
• Eddie Turner Ranked #13 On The Power List Of The Top 200 Biggest Voices In Leadership In 2023
• The Data Economics Company and Gordian Knot Strategies Announce Enkrateia Climate Investment Decision Support Platform

Under the terms of the agreement, ONO will provide KSQ a double-digit million upfront and potential near-term milestone payments with potential long-term value into the triple-digit millions as well as royalties based on net sales.

About KSQ Therapeutics

KSQ Therapeutics is advancing a pipeline of tumor- and immune-focused drug candidates to treat cancer and autoimmune disease across multiple drug modalities, including targeted therapies, adoptive cell therapies, and immunotherapies. KSQ's proprietary CRISPRomics^® discovery engine enables genome-scale, in vivo validated, unbiased drug discovery across broad therapeutic areas. For more information, please visit the company's website at www.ksqtx.com and follow @ksq_tx on Twitter.

More on Boston Chron

• Best Pneumatic Air Jack for Cars (2023): VEVOR 5T Bag Air Jack Reviewed by Compare Before Buying
• Americana Songstress Emma Jo To Release Powerful New Single, 'Straight Into Mine'
• Bain Capital Specialty Finance, Inc. Schedules Earnings Release for the Fourth Quarter and Fiscal Year Ended December 31, 2022
• Boston: Mayor Michelle Wu, Superintendent Mary Skipper and Green New Deal Director Oliver Sellers-Garcia celebrate start of school bus fleet electrification
• IISE announces leadership election results

About Ono Pharmaceutical Co., Ltd.

Ono Pharmaceutical Co., Ltd., headquartered in Osaka, is an R&D-oriented pharmaceutical company committed to creating innovative medicines in specific areas. Ono focuses its research on oncology, immunology, neurology and specialty research with high medical needs as priority areas for discovery and development of innovative medicines. For further information, please visit the company's website at https://www.ono-pharma.com/en.

Contacts

Media:
Cory Tromblee
cory@scientpr.com

---

Show All News | Report Violation